---
document_datetime: 2023-09-21 21:16:30
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/pioglitazone-teva-pharma-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: pioglitazone-teva-pharma-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.8552511
conversion_datetime: 2025-12-23 23:46:01.231618
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

## Pioglitazone Teva Pharma (SRD)

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                          | Opinion/ Notification 1 issued on Product   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IA/0024              | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                  | 12/01/2021                                  | 17/06/2021                                  | Annex II and PL                  |           |
| WS/1791              | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. The RMP was updated to the RMP template rev 2 as | 11/06/2020                                  | 17/06/2021                                  | Annex II                         |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

Medicinal Product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | GVP module V rev 2, and the existing additional risk minimisation measures (educational pack for the healthcare professionals containing a prescriber guide) were removed both from the RMP and their key elements from the Annex IID of the PI, in line with the originator product for pioglitazone. In addition, standard wording was reinstated for the PSUR submission requirement with a reference to the updates included in the EURD list. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required   | no                                                  | longer authorised   | per       |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------|---------------------|-----------|
| N/0022    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 05/04/2019 17/06/2021 28/11/2018 28/11/2018 Product | PL                  |           |
| N/0021    | Minor change in labelling or package leaflet not with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 31/01/2018                                          | PL                  | connected |
| IAIN/0020 | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 14/12/2017                                          | Annex II and PL     |           |
| N/0019    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 28/11/2017 28/11/2018                               | PL                  |           |

<div style=\"page-break-after: always\"></div>

| IB/0018/G   | This was an application for a group of variations. B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.f.1.e - Stability of FP - Change to an approved stability protocol   | 26/07/2017         | n/a                  | authorised                                                                                                                                                                                                                                                                             |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0017      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                           | 15/03/2017         | 28/11/2018 PL longer |                                                                                                                                                                                                                                                                                        |
| IA/0016     | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                              | 20/02/2017         | n/a no               |                                                                                                                                                                                                                                                                                        |
| R/0013      | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                    | 15/12/2016 Product | 17/02/2017           | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Pioglitazone Teva Pharma in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IA/0015     | B.II.a.3.b.1 - Changes in the composition (excipients) of the finished product - Other excipients - Any minor adjustment of the quantitative composition of the finished product with respect to excipients Medicinal                                                                                                                                                                      | 02/02/2017         | n/a                  |                                                                                                                                                                                                                                                                                        |
| IB/0014     | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure                                                                                                                                                                                                                                                                                           | 10/10/2016         | 18/11/2016           | SmPC and PL                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                                                                                                                                                                                                     |            |            |                                  |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|
| IB/0012   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                      | 19/07/2016 | 18/11/2016 | SmPC, Annex II, Labelling and PL |
| IA/0011/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites | 29/06/2016 | n/a        | longer authorised                |
| IA/0010   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                     | 25/04/2016 |            | 18/11/2016 PL                    |
| IAIN/0009 | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing Product no                                                                 | 27/11/2015 | 18/11/2016 | Annex II and PL                  |
| T/0008    | Transfer of Marketing Authorisation Medicinal                                                                                                                                                                                                                                                                     | 22/12/2014 | 30/01/2015 | SmPC, Labelling and PL           |

<div style=\"page-break-after: always\"></div>

| IB/0007     | B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation                                                                                                                                                                                                                                                           | 19/09/2014   | n/a        |                                  |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|
| IB/0006     | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                    | 29/07/2014   | n/a        | authorised                       |
| IB/0004     | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                           | 16/06/2014   | n/a        | longer                           |
| IAIN/0005/G | This was an application for a group of variations. B.III.2.a.1 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - AS B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits Product | 23/05/2014   | n/a no     |                                  |
| IB/0003/G   | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH Medicinal                                                                        | 25/11/2013   | 16/12/2014 | SmPC, Annex II, Labelling and PL |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|             | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|
| IAIN/0002   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 21/05/2013 n/a                                                 |
| IAIN/0001/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes Medicinal Product no | 12/04/2013 16/12/2014 SmPC, Labelling and PL longer authorised |